Abstract: The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

Abstract: The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

Abstract: Fluorescent imaging systems for performing an endoscopic procedure, such as a retrograde cholangiopancreatography (ERCP) procedure may include a first light source for emitting light in the visible spectrum, or light in the near infrared (NIR) spectrum, or both. A light source bandpass filter may block the emitted light in the visible spectrum, or in the NIR spectrum, or both. A first sensor may be capable of detecting the light in the visible spectrum, or the light in the NIR spectrum, or both. A sensor bandpass filter may block the detected light in the visible spectrum, or in the NIR spectrum, or both. The first or a second light source, or the first or a second sensor, or combinations thereof, may be removably disposed on a duodenoscope.

Abstract: Fluorescent imaging systems for performing an endoscopic procedure, such as a retrograde cholangiopancreatography (ERCP) procedure may include a first light source for emitting light in the visible spectrum, or light in the near infrared (NIR) spectrum, or both. A light source bandpass filter may block the emitted light in the visible spectrum, or in the NIR spectrum, or both. A first sensor may be capable of detecting the light in the visible spectrum, or the light in the NIR spectrum, or both. A sensor bandpass filter may block the detected light in the visible spectrum, or in the NIR spectrum, or both. The first or a second light source, or the first or a second sensor, or combinations thereof, may be removably disposed on a duodenoscope.

Abstract: The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

Abstract: The disclosure relates to benzoxaborole containing polymers and to methods of using the same to treat metabolic and gastrointestinal disorders.

Abstract: The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

Abstract: The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

Abstract: The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

Abstract: The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

Abstract: The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

Abstract: The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

Abstract: The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

Abstract: The disclosure relates to cationic boronic acid containing polymers and to methods of using the same to treat metabolic and gastrointestinal disorders.

Abstract: The present invention provides compositions and methods for treatment of metabolic syndromes. Namely, the presently disclosed compositions and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic disorders. The compositions include components for forming luminal barriers within the gastrointestinal tract of a subject where the barrier is created in-situ via interaction of resident mucin with the mucin-interacting agent.

Abstract: An implantable, body-driven shunt pump includes a pump body defining a fluid inlet, a fluid outlet and a fluid chamber therebetween; an inlet valve arranged in the fluid inlet, the inlet valve being a one-way valve arranged such that it is operable to allow fluid flow into the fluid chamber and to prevent fluid flow out of the fluid chamber; and an outlet valve arranged in the fluid outlet, the outlet valve being a one-way valve arranged such that it is operable to allow fluid flow out of the fluid chamber and to prevent fluid flow into the fluid chamber. The pump body includes an expandable and contractible component in a portion of the pump body that defines the fluid chamber such that the fluid chamber changes volume in response to a change in pressure of fluid in the fluid chamber.

Abstract: Fluorescent imaging systems for performing an endoscopic procedure, such as a retrograde cholangiopancreatography (ERCP) procedure may include a first light source for emitting light in the visible spectrum, or light in the near infrared (NIR) spectrum, or both. A light source bandpass filter may block the emitted light in the visible spectrum, or in the NIR spectrum, or both. A first sensor may be capable of detecting the light in the visible spectrum, or the light in the NIR spectrum, or both. A sensor bandpass filter may block the detected light in the visible spectrum, or in the NIR spectrum, or both. The first or a second light source, or the first or a second sensor, or combinations thereof, may be removably disposed on a duodenoscope.

Abstract: Devices for and methods of treatment of metabolic syndromes are disclosed. Namely, the presently disclosed devices and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic syndromes. In some embodiments, the devices include multilayered bioadhesive patches delivered orally by dissolvable ingestible capsule, wherein various mechanisms are provided for anchoring the bioadhesive patches to the duodenal mucosa.

Abstract: The present invention provides compositions and methods for treatment of metabolic syndromes. Namely, the presently disclosed compositions and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic disorders. The compositions include components for forming luminal barriers within the gastrointestinal tract of a subject where the barrier is created in-situ via interaction of resident mucin with the mucin-interacting agent.

Abstract: An implantable, body-driven shunt pump includes a pump body defining a fluid inlet, a fluid outlet and a fluid chamber therebetween; an inlet valve arranged in the fluid inlet, the inlet valve being a one-way valve arranged such that it is operable to allow fluid flow into the fluid chamber and to prevent fluid flow out of the fluid chamber; and an outlet valve arranged in the fluid outlet, the outlet valve being a one-way valve arranged such that it is operable to allow fluid flow out of the fluid chamber and to prevent fluid flow into the fluid chamber. The pump body includes an expandable and contractible component in a portion of the pump body that defines the fluid chamber such that the fluid chamber changes volume in response to a change in pressure of fluid in the fluid chamber.